Roivant Sciences ROIV
NASDAQ ROIV
$41.89 +0.41 (+0.99%)
As of: Sep 9, 2026 · 11:53 AM EDT

Roivant Sciences (ROIV) Other Non Operating Income (2020 - 2026)

Roivant Sciences' (ROIV) quarterly Other Non Operating Income came in at -$2.1 million in Q2 2026, up 81.0% on a YoY basis from -$1.2 million in Q2 2025, and up 75.12% quarter-over-quarter from -$8.6 million in Q4 2025.

Analysis

Roivant Sciences (ROIV) Other Non Operating Income (2020 - 2026) Analysis & Trends

Roivant Sciences (ROIV) has reported Other Non Operating Income for 7 consecutive years, with -$2.1 million the latest figure, recorded in Q2 2026.

  • For the quarter ending Q2 2026, Other Non Operating Income rose 81.0% year-over-year to -$2.1 million; the trailing twelve-month figure through Jun 2026 stood at -$27.6 million (down 14.27% YoY), and the FY2026 full-year result was $11.0 million, up 202.85% from the prior year.
  • Other Non Operating Income climbed to -$2.1 million in Q2 2026 per ROIV's latest filing, from -$8.6 million in the prior quarter.
  • Across five years, Other Non Operating Income topped out at $29.3 million in Q4 2022 and bottomed at -$11.2 million in Q2 2025.
  • Historically, Other Non Operating Income has averaged $3.4 million across 5 years, with a median of -$1.5 million in 2024.
  • The widest YoY moves for Other Non Operating Income: up 1257.61% in 2022, down 909.7% in 2022.
  • Over 5 years, Other Non Operating Income stood at $29.3 million in 2022, then sank by 40.72% to $17.4 million in 2023, then tumbled by 145.39% to -$7.9 million in 2024, then declined by 8.67% to -$8.6 million in 2025, then jumped by 75.12% to -$2.1 million in 2026.
  • According to Business Quant data, Other Non Operating Income over the past three periods registered -$2.1 million, -$8.6 million, and -$5.7 million for Q2 2026, Q4 2025, and Q3 2025 respectively.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Amgen 212.13 Bn 198.14 Bn 7.24 Bn
2 Gilead Sciences 181.95 Bn 178.77 Bn 6.22 Bn
3 Vertex Pharmaceuticals 132.50 Bn 124.65 Bn 2.84 Bn
4 Regeneron Pharmaceuticals 82.67 Bn 74.68 Bn 3.93 Bn
5 Argenx Se 61.55 Bn 56.37 Bn 1.37 Bn
6 Moderna 54.65 Bn 49.51 Bn 52.00 Mn
7 Alnylam Pharmaceuticals 34.23 Bn 30.92 Bn 992.69 Mn
8 Biogen 31.46 Bn 30.18 Bn 1.96 Bn
9 Roivant Sciences 30.19 Bn 30.19 Bn 1.16 Mn
10 Insmed 27.89 Bn 26.72 Bn 358.27 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -2.13 Mn
Dec 31, 2025 -8.56 Mn
Sep 30, 2025 -5.69 Mn
Jun 30, 2025 -11.21 Mn
Dec 31, 2024 -7.88 Mn
Sep 30, 2024 -1.45 Mn
Jun 30, 2024 -3.61 Mn
Dec 31, 2023 17.35 Mn
Sep 30, 2023 17.35 Mn
Jun 30, 2023 4.59 Mn
Dec 31, 2022 29.28 Mn
Sep 30, 2022 16.76 Mn
Jun 30, 2022 -1.09 Mn
Dec 31, 2021 -2.53 Mn
Sep 30, 2021 -3.69 Mn
Jun 30, 2021 134,000.00
Dec 31, 2020 5.79 Mn
Sep 30, 2020 757,000.00
Jun 30, 2020 -2.84 Mn